Tempest Achieves Key Manufacturing Milestone for Lead CAR-T Therapy TPST-2003, Paving Way for Pivotal Study
summarizeSummary
Tempest Therapeutics announced a key manufacturing milestone for its lead dual-targeting CAR-T therapy, TPST-2003, for relapsed/refractory multiple myeloma. The company's manufacturing partner received the lentiviral vector, a critical component for TPST-2003 production. This achievement is crucial as it enables Tempest to proceed with manufacturing activities required for a potentially registrational study later this year. This progress is particularly significant for the micro-cap company, which recently disclosed a 'going concern' warning in its 10-K but highlighted a strategic pivot into CAR-T cell therapy with strong early data for TPST-2003. Investors will now monitor for the initiation of the registrational study and the presentation of updated clinical results later this year.
في وقت هذا الإعلان، كان TPST يتداول عند ١٫٨٧ US$ في NASDAQ ضمن قطاع Life Sciences، مع قيمة سوقية تقارب ٢٥٫٤ مليون US$. تراوح نطاق التداول خلال 52 أسبوعًا بين ١٫٥٠ US$ و١٢٫٢٣ US$. تم تقييم هذا الخبر على أنه ذو معنويات سوقية إيجابية وبدرجة أهمية ٧ من 10. المصدر: GlobeNewswire.